Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Dabrafenib

Dabrafenib

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Dabrafenib

22 trials tracked of Dabrafenib: 4 in phase 3 or 4 and 1 with published results. The most-cited published study has 30 citations.

22Trials tracked
4Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 4 Phase 2 17 Other / NA 1
  1. Phase 3 Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes Completed · 30 cited
  2. Phase 3 Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma Completed
  3. Phase 3 A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma Completed
  4. Phase 3 Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). Completed
  5. Phase 2 Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease Completed
  6. Phase 2 Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer Completed
Show 16 more trials
  1. Phase 2 Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations Completed
  2. Phase 2 Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation Completed
  3. Phase 2 Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part) Completed
  4. Phase 2 Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma Completed
  5. Phase 2 Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors Completed
  6. Phase 2 Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer Completed
  7. Phase 2 BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) Completed
  8. Phase 2 Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma Completed
  9. Phase 2 A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC Completed
  10. Phase 2 Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers Completed
  11. Phase 2 A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects Completed
  12. Phase 2 A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) Completed
  13. Phase 2 Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. Completed
  14. Phase 2 Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain Completed
  15. Phase 2 MCS110 With BRAF/MEK Inhibition in Patients With Melanoma Completed
  16. N/A Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US Completed

Showing the 22 most-cited and recently-updated of 22 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.